CRBP vs NVO
CRBP: Corbus Pharmaceuticals is a clinical-stage biotechnology company developing a Nectin-4-targeting antibody-drug conjugate for cancer and a novel CB1 inverse agonist for obesity. NVO: A global leader in the development of pharmaceutical treatments for diabetes, obesity, and rare chronic diseases, anchored by its prominent GLP-1 therapy portfolio.
Side-by-side fundamentals
| Metric | CRBP | NVO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $5.27 | $38.18 | |
| Market cap | $102M | $206.0B | |
| P/E as of 2026-09-03 | n/a | 11.40 | |
| Net margin FY2025, SEC XBRL | n/a | +33.1% | |
| Gross margin FY2025, SEC XBRL | n/a | +81.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +41.3% | |
| ROE FY2025, SEC XBRL | -53.2% | +52.8% | NVO higher |
| ROA FY2025, SEC XBRL | -46.7% | +18.9% | NVO higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.63 | CRBP lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +5.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +20.4% | |
| Dividend yield as of 2026-09-03 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 1.08 | 0.81 | |
| 1-year return as of 2026-10-08 close | -60.7% | -36.0% | NVO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.